#3

lovE Variant Regulator Molecules
(Atty Docket No. 109272.150; Client Docket No. MIC005US)

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to the fields of microbiology and molecular biology. In particular, the invention relates to the field of mycology and the production of secondary metabolites from fungi.

Summary of the Related Art

Secondary metabolites are a major source of commercially useful products such as food additives, vitamins, and medicines for the treatment of a wide variety of infections and diseases. By way of example, in 1997 the statin drugs lovastatin, simvastatin, and pravastatin, fungal secondary metabolites used in the treatment of hypercholesteremia, together had US sales of US$7.53 billion (Sutherland *et al.*, *Current Opinion In Drug Discovery & Development* **4**:229-236 (2001)). The cost and availability of these plant, bacterial and fungal metabolites are frequently determined by limitations imposed on production and purification of these compounds from culture. This problem is frequently exacerbated by the fact that these products are generally produced during the stationary phase of bacterial and fungal growth.

A wide variety of methods have been utilized to increase the amount of secondary metabolite produced in culture. Studies have demonstrated the importance of carefully designing the medium in which a fungus is grown to maximize the amount of a secondary metabolite produced (see, *e.g.*, Hajjaj H, *et al.*, *Appl. Environ. Microbiol.* **67**:2596-602 (2001); Lesova, K., *et al.*, *J. Basic Microbiol.* **40**:369-75 (2000)). In addition, the method of

culture or fermentation also impacts directly on the amount of secondary metabolite produced. For example, see Robinson, T., *et al.* (*Appl. Microbiol. Biotechnol.* **55**:284-289 (2001)), which demonstrates the advantages of solid state (substrate) fermentation.

In addition to the manipulation of culture and media conditions, genetic approaches have been taken to increase secondary metabolite production. For example, the production of penicillin is limited by the activity of two enzymes, encoded by the *ipnA* and *acvA* genes, both of which are regulated by the *pacC* protein, a zinc-finger transcription factor. Naturally occurring mutant alleles of the *pacC* locus are known to possess more transcription-activating activity than the cognate, wild-type allele (see, *e.g.*, Tilburn *et al. EMBO J.* **14(4)**:779-790 (1995)). Thus, one genetic approach to increasing secondary metabolite production is to identify and isolate naturally occurring mutant alleles, the expression of which leads to increased secondary metabolite production.

Although many regulators of secondary metabolite production in many organisms are known, not all of the organisms that produce secondary metabolites are amenable to genetic or molecular genetic manipulation. Thus, these systems are not generally useful as a source for the isolation of naturally occurring mutant alleles and are even less useful for the deliberate manipulation of secondary metabolite regulator protein structure with the aim of creating improved regulators of secondary metabolite production.

It would be advantageous to have improved regulators of the biosynthetic enzymes responsible for secondary metabolite production. For example, recent studies suggest increasing usage of statin drugs, e.g., see Waters D.D., *Am. J. Cardiol.* **88**:10F-5F (2001)). Thus,

demand for statin drugs is likely to increase substantially. In order to meet the demand for these and other secondary metabolites, new and improved methods for the production of secondary metabolites must be identified.

BRIEF SUMMARY OF THE INVENTION

The invention provides improved secondary metabolite regulator proteins that enable increased production of secondary metabolites. The invention also provides methods to make these improved regulator proteins.

In a first aspect, the invention provides a variant regulator protein of secondary metabolite production with increased activity than that of the cognate, wild-type protein. In certain embodiments of this aspect of the invention, the regulator protein is a fungal regulator protein.

In an embodiment of the first aspect, the invention provides an improved regulator protein comprising an amino acid sequence coding for a variant lovE protein having at least one specific mutation that gives rise to greater transcription-activating properties of the regulator protein and/or induction of secondary metabolite synthesis.

By way of non-limiting example, certain preferred regulator proteins of this aspect of the invention include at least one of the following mutations: (1) a Group 6 amino acid residue mutated to a Group 2 amino acid residue at position 31, in one embodiment the mutation represented by F31L; (2) a Group 3 amino acid residue mutated to a Group 5 amino acid residue at position 41, in one embodiment the mutation represented by Q41K or Q41R; (3) a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 52, in one embodiment the mutation represented by T52I; (4) a Group 4 amino acid residue mutated to a Group 3 amino acid residue at position 52, in one embodiment the mutation represented by T52N; (5) a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 73, in one embodiment the mutation represented by C73R; (6) a Group 1 amino acid residue mutated to a Group 4 amino

acid residue at position 101, in one embodiment the mutation represented by P101S; (7) a Group 1 amino acid residue mutated to a Group 3 amino acid residue at position 101, in one embodiment the mutation represented by P101Q; (8) a valine amino acid residue mutated to another Group 2 amino acid residue at position 111, in one embodiment the mutation represented by V111I; (9) a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 133, in one embodiment the mutation represented by S133L; (10) a Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 141, in one embodiment the mutation represented by E141V; (11) a Group 3 amino acid residue mutated to a Group 5 amino acid residue at position 141, in one embodiment the mutation represented by E141K; (12) a Group 4 amino acid residue mutated to Group 6 amino acid residue at position 153, in one embodiment the mutation represented by C153Y; (13) a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 153, in one embodiment the mutation represented by C153R; (14) a Group 4 amino acid residue mutated to a Group 1 amino acid residue at position 281, in one embodiment the mutation represented by T281A; (15) a Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 367, in one embodiment the mutation represented by N367I; (16) a Group 3 amino acid residue mutated to a Group 6 amino acid residue at position 367, in one embodiment the mutation represented by N367Y; (17) a Group 1 amino acid residue mutated to Group 4 amino acid residue at position 389, in one embodiment the mutation represented by P389S; and (18) a Group 1 amino acid residue mutated to a Group 2 amino acid residue at position 389, in one embodiment the mutation represented by P389L.

In some embodiments of the first aspect, the invention provides regulator proteins with at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen of the above described specific mutations.

In other embodiments of the first aspect, the invention provides an isolated lovE variant regulator protein selected from the group consisting of SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, and SEQ ID NO:65.

In a second aspect, the invention provides a nucleic acid molecule encoding a lovE regulator of the first aspect of the invention. By way of non-limiting example, the invention provides a nucleic acid molecule encoding the lovE variant regulator protein selected from the group consisting of SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, and SEQ ID NO:90.

In a third aspect, the invention provides a method of increasing the activity of a protein that regulates secondary metabolite production comprising: (a) selecting a nucleic acid comprising a polynucleotide encoding a protein regulator of secondary metabolite production; (b)

mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; and (c) selecting a variant regulator protein with more activity than the cognate, wild-type protein.

In various embodiments of the third aspect, the secondary metabolite is a fungal secondary metabolite. In certain embodiments of the third aspect, the protein regulator of secondary metabolite production is a transcription factor. In certain embodiments of the third aspect, the protein regulator of secondary metabolite production is a transmembrane transporter, protein that mediates secretion, kinase, G-protein, cell surface receptor, GTPase activating protein, guanine nucleotide exchange factor, phosphatase, protease, phosphodiesterase, bacterial protein toxin, importin, RNA-binding protein, SCF complex component, adherin, or protein encoded within a biosynthetic cluster. In certain other embodiments of the third aspect, the variant regulator protein is selected to have more activity in a heterologous cell and/or more activity in a homologous cell than the cognate, wild-type regulator protein. In certain embodiments, the variant regulator protein is selected to have more activity in a heterologous cell and/or more activity in a homologous cell than the cognate, wild-type protein and to cause more secondary metabolite to be produced in a homologous cell and/or a heterologous cell when compared to the cognate, wild-type regulator protein. In a particularly preferred embodiment, the variant regulator protein is a lovE variant regulator protein.

In a fourth aspect, the invention provides a method of increasing production of a secondary metabolite comprising: (a) selecting a nucleic acid comprising a

polynucleotide encoding a protein regulator of secondary metabolite production; (b) mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; (c) selecting a variant regulator protein with more activity than the cognate, wild-type protein; and (d) expressing the selected variant regulator protein in a cell, thereby increasing production of the secondary metabolite in the cell.

In various embodiments of the fourth aspect, the secondary metabolite is a fungal secondary metabolite. In certain embodiments of the third aspect, the protein regulator of secondary metabolite production is a transcription factor. In certain embodiments of the fourth aspect, the protein regulator of secondary metabolite production is a transmembrane transporter, a protein that mediates secretion, a kinase, a G-protein, a cell surface receptor, a GTPase activating protein, a guanine nucleotide exchange factor, a phosphatase, a protease, a phosphodiesterase, a bacterial protein toxin, an importin, an RNA-binding protein, an SCF complex component, an adherin, or a protein encoded within a biosynthetic cluster. In certain other embodiments of the fourth aspect, the variant regulator protein is selected to have more activity in a heterologous cell and/or more activity in a homologous cell. In certain embodiments, the variant regulator protein is selected to have more activity in a heterologous cell and/or more activity in a homologous cell and to cause more secondary metabolite to be produced in a homologous cell and/or a heterologous cell when compared to the cognate, wild-type regulator protein. In a particularly preferred

embodiment, the variant regulator protein is a lovE variant regulator protein.

In a fifth aspect, the invention provides an isolated variant regulator protein of secondary metabolite production having increased activity compared to a cognate, wild-type protein, the variant regulator protein made by the process comprising: (a) selecting a nucleic acid comprising a polynucleotide encoding a protein regulator of secondary metabolite production; (b) mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; (c) selecting a variant regulator protein with more activity than the cognate, wild-type protein; and (d) recovering the selected variant regulator protein.

In certain embodiments of the fifth aspect, the secondary metabolite is a fungal secondary metabolite. In certain embodiments of the fifth aspect, the protein regulator of secondary metabolite production is a transcription factor. In certain embodiments of the fifth aspect, the protein regulator of secondary metabolite production is a transmembrane transporter, a protein that mediates secretion, a kinase, a G-protein, a cell surface receptor, a GTPase activating protein, a guanine nucleotide exchange factor, a phosphatase, a protease, a phosphodiesterase, a bacterial protein toxin, an importin, an RNA-binding protein, an SCF complex component, an adherin, or a protein encoded within a biosynthetic cluster. .In certain embodiments of the fifth aspect, the variant regulator protein has more activity in a heterologous and/or a homologous cell than the cognate, wild-type protein. In certain embodiments of the fourth aspect, the variant regulator protein

increases production of a secondary metabolite in a heterologous cell and/or a homologous cell when compared to the cognate, wild-type protein. In a particularly preferred embodiment, the variant regulator protein is a lovE variant regulator protein.

In a sixth aspect, the invention provides a fungus having improved lovastatin production made by the process of transforming a fungal cell with a nucleic acid molecule encoding a lovE variant protein of the first aspect of the invention. In an embodiment thereof, the nucleic acid molecule is selected from a nucleic acid molecule of the second aspect of the invention.

In a seventh aspect, the invention provides an improved process for making lovastatin comprising transforming a fungal cell with a nucleic acid molecule encoding a variant of the lovE protein of the first aspect of the invention. In an embodiment thereof, the fungal cell is transformed with a nucleic acid molecule of the second aspect of the invention.

In a eighth aspect, the invention provides a nucleic acid molecule encoding a lovE protein defined by SEQ ID NO:91. In an embodiment thereof, the invention provides an isolated *lovE* nucleic acid molecule defined by SEQ ID NO:92.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photographic representation of cells growing on media with and without G418 selection demonstrating *lovF*p-*HIS3*p-Neo activation in *S. cerevisiae*. Controls include MB968 (vector only), MB2478 (lowly expressed wild-type *lovE*), and MB1644 (highly expressed wild-type *lovE*). All *lovE* variants are expressed in an MB968 vector backbone similar to MB2478.

Figure 2A is a graphic representation of *lovF*p-*CYC1*p-*lacZ* expression in *S. cerevisiae* strains expressing lovE variant proteins from the clones *lovE* 1-10.

Figure 2B is a graphic representation of *lovF*p-*CYC1*p-*lacZ* expression in *S. cerevisiae* strains expressing lovE variant proteins from the clones *lovE* 1-10 from a separate transformation than that of Figure 2A.

Figure 3 is a graphic presentation of *lovF*p-*CYC1*p-lacZ expression in *S. cerevisiae* strains expressing lovE variant proteins from clones *lovE* 16-41.

Figure 4 is a graphic presentation of *lovF*p-lacZ expression in *S. cerevisiae* strains expressing *lovE* variant proteins from clones *lovE* 1-10.

Figure 5 is a graphic presentation of *lovF*p-lacZ expression in *S. cerevisiae* strains expressing lovE variant proteins from clones *lovE* 16, 20, 21, 30-34, and 36-41.

Figure 6 is a graphic presentation of lovastatin culture concentration, as measured by enzyme inhibition

assay, from broths of *A. terreus* cultures expressing *lovE* variant proteins 1-10 in.

Figure 7A is a graphic depiction of lovastatin culture concentration, as measured by HPLC analysis, from broths of *A. terreus* cultures expressing lovE variant proteins 1-10 in MF117.

Figure 7B is a graphic depiction of lovastatin culture concentration, as measured by HPLC analysis, from broths of *A. terreus* cultures expressing lovE variant proteins 2, 6, 30, 32, 36, 37, 39, and 41 in MF117.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The patents and publications cited herein reflect the level of knowledge in the art and are hereby incorporated by reference in their entirety. Any conflict between any teaching of such references and this specification shall be resolved in favor of the latter.

The invention utilizes techniques and methods common to the fields of molecular biology, genetics and microbiology. Useful laboratory references for these types of methodologies are readily available to those skilled in the art. See, for example, Molecular Cloning, A Laboratory Manual, 3rd edition, edited by Sambrook, J., MacCallum, P., and Russell, D.W. (2001), Cold Spring Harbor Laboratory Press (ISBN: 0-879-69576-5); Current Protocols In Molecular Biology, edited by Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Struhl, K. (1993), John Wiley and Sons, Inc. (ISBN: 0-471-30661-4); PCR Applications: Protocols for Functional Genomics, edited by Innis, M.A., Gelfand, D.H., Sninsky, J.J. (1999), Cold Spring Harbor Press (ISBN: 0-123-72186-5); and Methods In Yeast Genetics, 2000 Edition: A Cold Spring Habor Laboratory Course Manual, by Burke, D., Dawson, D. and Stearns, T., Cold Spring Harbor Press (ISBN: 0-879-69588-9).

In certain embodiments of the aspects of the invention, the invention relates to the biosynthesis and improved production of secondary metabolites. The invention provides variant regulator proteins useful for the production of secondary metabolites, nucleic acid molecules encoding variant regulator proteins, and methods for their production.

In a first aspect, the invention provides a variant regulator protein of secondary metabolite production with increased activity relative to a cognate, wild-type

regulator protein. Particularly preferred are variant regulator proteins of fungal secondary metabolites.

As used herein, the terms "fungal" and "fungus" refer generally to eukaryotic, heterotrophic organisms with an absorptive mode of nutrition. Fungi typically contain chitin in their cell walls and exhibit mycelial or yeast-like growth habits (More Gene Manipulations in Fungi, edited by J.W. Bennet and L.L. Lasure, Academic Press Inc. (1991), ISBN 0120886421). More specifically, the terms refer to secondary metabolite producing organisms including, without limitation, *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp.* and *Phaffia rhodozyma* (See, Fungal Physiology, Chapter 9 (Secondary(Special) Metabolism), Griffin, D. H., John Wiley & Sons, Inc.; ISBN: 0471166154).

The term "variant regulator protein" is used herein to refer to any regulatory protein having at least one change or difference in the amino acid sequence of the protein when compared to its cognate, wild-type regulatory protein sequence. The term does not include naturally occurring allelic variations of the cognate, wild-type regulatory protein.

The term "regulator protein" is meant to refer to a protein having a positive or negative function that modifies the production of a secondary metabolite. The function of the protein may be at the level of transcription, e.g., repression or activation, protein synthesis, or transport. The regulator may alter the level of transcription, RNA stability, translation, post-

translational modification, or cellular localization of proteins involved in secondary metabolite synthesis and/or transport. The regulator may also have effects on precursor metabolite pools, flux through specific pathways and metabolite resistance.

By way of non-limiting example, certain embodiments of the aspects of the invention relate to a regulator protein that is a protein that contributes and/or promotes transcription of a gene sequence, *i.e.*, a transcription-activating protein. "Transcription-activating" is a term used to refer to characteristics of a protein that promote transcription. As used herein, a transcription-activating protein would include proteins that increase accessibility of the DNA to transcription complexes, for example, by opening or relaxing chromatin structure, proteins that promote the recognition and/or binding of transcription complexes to a target gene sequence, and/or proteins that promote transcription complex movement along the length of the template DNA sequence.

Regulatory proteins of secondary metabolite production and the nucleic acid sequences encoding these are known to those skilled in the art. Non-limiting examples of regulatory proteins of secondary metabolite synthesis include: regulator proteins of the aflatoxin/sterigmatocystin biosynthetic cluster (Woloshuk, C.P., *et al.*, *Appl, Environ. Microbiol.* **60**:2408-2414 (1994) and Brown, D.W., *et al.*, *Proc Natl Acad Sci U S A.* **93**:1418-1422 (1996)); regulator proteins of the paxilline biosynthetic cluster (Young, C., *et al.*, *Mol, Microbiol.* **39**:754-764 (2001)); regulator proteins of the cephalosporin and penicillin biosynthetic clusters (Litzka O., *et al.*, *Antonie Van Leeuwenhoek* **75**:95-105 (1999); Schmitt E.K. and Kuck U., *J. Biol. Chem.* **275**:9348-9357 (2000); MacCabe *et al. Mol. Gen. Genet.*

250:367-374 (1996); Suarez *et al. Mol. Microbiol.* **20**:529-540 (1996); Lambert *et al. Mol. Cell. Biol.* **17**:3966-3976 (1997); Su *et al. Genetics* **133**:67-77 (1993); regulator proteins of tricothecene synthesis (Trapp S.C., *et al., Mol. Gen. Genet.* **257**:421-432 (1998); Brown D.W., *et al., Fungal Genet. Biol.* **32**:121-133 (2001); and Matsumoto G., *et al. Biosci. Biotechnol. Biochem.* **63**:2001-2004 (1999)); and regulator proteins of lovastatin synthesis (Kennedy, J., *et al., Science* **284**:1368-1372 (1999); Hendrickson *et al., Chem. Biol.* **6**:429-439 (1999) Tag, A. *et al., Mol Microbiol.* **38**:658-65 (2000)).

Certain embodiments of the aspects of the invention disclosed herein relate to the lovE regulator protein, a protein which plays a key role in the biosynthesis of lovastatin. More particularly, certain embodiments of the aspects of the invention relate to variant proteins of the lovE regulator protein and methods of making the same. Such proteins are variant with respect to the following *A. terreus* wild-type *lovE* sequences (SEQ ID NOS:91 and 92).

Table 1: Amino Acid and Nucleic Acid Sequences of Wild-type *lovE*

***Wild-type lovE* Amino Acid Sequence**

maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrc
qqaglrcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssnts
rqfldppdsydwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekap
lppvssdiaraasaqrelfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrl
ltvlrqqaqadchqgtldeclrtknlftavhcyilnvriltaiselllsqirrtqnshms
plegsrsqspsrddtssssghssvdtipffsenlpigelfsyvdplthalfsacttlhvg
vqllreneitlgvhsaqgiaasismsgepgediartgatnsarceeqpttpaarvlfmfl
sdegafqeaksagsrgrtiaalrrcyedifslarkhkhgmlrdlnnipp (SEQ ID NO:91)

Wild-type lovE DNA Sequence

atggctgcagatcaaggtatattcacgaactcggtcactctctcgccagtggagggttca
cgcaccggtggaacattaccccgccgtgcattccgacgctcttgtgatcggtgtcatgca
caaaagatcaaatgtactggaaataaggaggttactggccgtgctccctgtcagcgttgc
cagcaggctggacttcgatgcgtctacagtgagcgatgccccaagcgcaagctacgccaa
tccagggcagcggatctcgtctctgctgacccagatccctgcttgcacatgtcctcgcct
ccagtgccctcacagagcttgccgctagacgtatccgagtcgcattcctcaaatacctcc
cggcaatttcttgatccaccggacagctacgactggtcgtggacctcgattggcactgac

gaggctattgacactgactgctgggggctgtcccaatgtgatggaggcttcagctgtcag
ttagagccaacgctgccggatctaccttcgcccttcgagtctacggttgaaaaagctccg
ttgccaccggtatcgagcgacattgctcgtgcggccagtgcgcaacgagagcttttcgat
gacctgtcggcggtgtcgcaggaactggaagagatccttctggccgtgacggtagaatgg
ccgaagcaggaaatctggacccatcccatcggaatgtttttcaatgcgtcacgacggctt
cttactgtcctgcgccaacaagcgcaggccgactgccatcaaggcacactagacgaatgt
ttacggaccaagaacctctttacggcagtacactgttacatattgaatgtgcggattttg
accgccatatcggagttgctcctgtcgcaaattaggcggacccagaacagccatatgagc
ccactggaagggagtcgatcccagtcgccgagcagagacgacaccagcagcagcagcggc
cacagcagtgttgacaccataccttctttagcgagaacctccctattggtgagctgttc
tcctatgttgacccccctgacacacgccctattctcggcttgcactacgttacatgttggg
gtacaattgctgcgtgagaatgagattactctgggagtacactccgcccagggcattgca
gcttccatcagcatgagcggggaaccaggcgaggatatagccaggacaggggcgaccaat
tccgcaagatgcgaggagcagccgaccactccagcggctcgggttttgttcatgttcttg
agtgatgaaggggctttccaggaggcaaagtctgctggttcccgaggtcgaaccatcgca
gcactgcgacgatgctatgaggatatcttttccctcgcccgcaaacacaaacatggcatg
ctcagagacctcaacaatattcctccatga (SEQ ID NO:92)

As used herein, the term "secondary metabolite" means a compound, derived from primary metabolites, that is produced by an organism, is not a primary metabolite, is not ethanol or a fusel alcohol, and is not required for growth under standard conditions. Secondary metabolites are derived from intermediates of many pathways of primary metabolism. These pathways include, without limitation, pathways for biosynthesis of amino acids, the shikimic acid pathway for biosynthesis of aromatic amino acids, the polyketide biosynthetic pathway from acetyl coenzyme A (CoA), the mevalonic acid pathway from acetyl CoA, and pathways for biosynthesis of polysaccharides and peptidopolysaccharides. Collectively, secondary metabolism involves all primary pathways of carbon metabolism. Particularly preferred in embodiments of the aspects of the invention are fungal secondary metabolites (*See*, Fungal Physiology, Chapter 9 (Secondary(Special) Metabolism), Griffin, D. H., John Wiley & Sons, Inc.; ISBN: 0471166154).

"Secondary metabolite" also includes intermediate compounds in the biosynthetic pathway for a secondary metabolite that are dedicated to the pathway for

synthesis of the secondary metabolite. "Dedicated to the pathway for synthesis of the secondary metabolite" means that once the intermediate is synthesized by the cell, the cell will not convert the intermediate to a primary metabolite. "Intermediate compounds" also include secondary metabolite intermediate compounds which can be converted to useful compounds by subsequent chemical conversion or subsequent biotransformation. As such, providing improved availability of such intermediate compounds would still lead to improved production of the ultimate useful compound, which itself may be referred to herein as a secondary metabolite. The yeast *Saccharomyces cerevisiae* is not known to produce secondary metabolites.

The term "primary metabolite" means a natural product that has an obvious role in the functioning of almost all organisms. Primary metabolites include, without limitation, compounds involved in the biosynthesis of lipids, carbohydrates, proteins, and nucleic acids. The term "increasing the yield of the secondary metabolite" means increasing the quantity of the secondary metabolite present in the total fermentation broth per unit volume of fermentation broth or culture.

As used herein, the phrase "modulate production of a secondary metabolite" refers to a positive or negative or desirable change in one or more of the variables or values that affect the process or results of production of the primary or secondary metabolites in a liquid or solid state fungal fermentation. These positive or negative or desirable changes include, without limitation, an increase or decrease in the amount of a primary or secondary metabolite being produced (in absolute terms or in quantity per unit volume of fermentation broth or per unit mass of solid substrate);

a decrease in the volume of the broth or the mass/quantity of substrate required for the production of sufficient quantities; a decrease in the cost of raw materials and energy, the time of fermentor or culture run, or the amount of waste that must be processed after a fermentor run; an increase or decrease in the specific production of the desired metabolite (both in total amounts and as a fraction of all metabolites and side products made by the fungus); an increase or decrease in the percent of the produced secondary metabolite that can be recovered from the fermentation broth or culture; and an increase in the resistance of an organism producing a primary or secondary metabolite to possible deleterious effects of contact with the secondary metabolite.

In certain embodiments of aspects of the invention, a secondary metabolite is an anti-bacterial. An "anti-bacterial" is a molecule that has cytocidal or cytostatic activity against some or all bacteria. Preferred anti-bacterials include, without limitation, β-lactams. Preferred β-lactams include, without limitation, penicillins and cephalosporins and biosynthetic intermediates thereof. Preferred penicillins and biosynthetic intermediates include, without limitation, isopenicillin N, 6-aminopenicillanic acid (6-APA), penicillin G, penicillin N, and penicillin V. Preferred cephalosporins and biosynthetic intermediates include, without limitation, deacetoxycephalosporin V (DAOC V), deacetoxycephalosporin C (DAOC), deacetylcephalosporin C (DAC), 7-aminodeacetoxycephalosporanic acid (7-ADCA), cephalosporin C, 7-B-(5-carboxy-5-oxopentanamido)-cephalosporanic acid (keto-AD-7ACA), 7-B -(4-carboxybutanamido)-cephalosporanic acid (GL-7ACA), and 7-aminocephalosporanic acid (7ACA).

In certain embodiments of aspects of the invention, the secondary metabolite is an anti-hypercholesterolemic or a biosynthetic intermediate thereof. An "anti-hypercholesterolemic" is a drug administered to a patient diagnosed with elevated cholesterol levels for the purpose of lowering the cholesterol levels. Preferred anti-hypercholesterolemics include, without limitation, lovastatin, mevastatin, simvastatin, and pravastatin.

According to other embodiments of the invention, a secondary metabolite is an immunosuppressant or a biosynthetic intermediate thereof. An "immunosuppressant" is a molecule that reduces or eliminates an immune response in a host when the host is challenged with an immunogenic molecule, including immunogenic molecules present on transplanted organs, tissues or cells. Preferred immunosuppressants include, without limitation, members of the cyclosporin family and beauverolide L. Preferred cyclosporins include, without limitation, cyclosporin A and cyclosporin C.

In certain embodiments of aspects of the invention, the secondary metabolite is an ergot alkaloid or a biosynthetic intermediate thereof. An "ergot alkaloid" is a member of a large family of alkaloid compounds that are most often produced in the sclerotia of fungi of the genus Claviceps. An "alkaloid" is a small molecule that contains nitrogen and has basic pH characteristics. The classes of ergot alkaloids include clavine alkaloids, lysergic acids, lysergic acid amides, and ergot peptide alkaloids. Preferred ergot alkaloids include, without limitation, ergotamine, ergosine, ergocristine, ergocryptine, ergocornine, ergotaminine, ergosinine, ergocristinine, ergocryptinine, ergocorninine, ergonovine, ergometrinine, and ergoclavine.

In certain embodiments of aspects of the invention, the secondary metabolite is an inhibitor of angiogenesis

or a biosynthetic intermediate thereof. An "angiogenesis inhibitor" is a molecule that decreases or prevents the formation of new blood vessels. Angiogenesis inhibitors have proven effective in the treatment of several human diseases including, without limitation, cancer, rheumatoid arthritis, and diabetic retinopathy. Preferred inhibitors of angiogenesis include, without limitation, fumagillin and ovalicin.

In certain embodiments of aspects of the invention, the secondary metabolite is a glucan synthase inhibitor or a biosynthetic intermediate thereof. A "glucan synthase inhibitor" is a molecule that decreases or inhibits the production of 1,3-β-D-glucan, a structural polymer of fungal cell walls. Glucan synthase inhibitors are a class of antifungal agents. Preferred glucan synthase inhibitors include, without limitation, echinocandin B, pneumocandin B, aculeacin A, and papulacandin.

In certain embodiments of aspects of the invention, the secondary metabolite is a member of the gliotoxin family of compounds or a biosynthetic intermediate thereof. The "gliotoxin family of compounds" are related molecules of the epipolythiodioxopiperazine class. Gliotoxins display diverse biological activities, including, without limitation, antimicrobial, antifungal, antiviral, and immunomodulating activities. Preferred members of the "gliotoxin family of compounds" include, without limitation, gliotoxin and aspirochlorine.

In certain embodiments of aspects of the invention, the secondary metabolite is a fungal toxin or a biosynthetic intermediate thereof. A "fungal toxin" is a compound that causes a pathological condition in a host, either plant or animal. Fungal toxins could be mycotoxins present in food products, toxins produced by

phytopathogens, toxins from poisonous mushrooms, or toxins produced by zoopathogens. Preferred fungal toxins include, without limitation, aflatoxins, patulin, zearalenone, cytochalasin, griseofulvin, ergochrome, cercosporin, marticin, xanthocillin, coumarins, tricothecenes, fusidanes, sesterpenes, amatoxins, malformin A, phallotoxins, pentoxin, HC toxin, psilocybin, bufotenine, lysergic acid, sporodesmin, pulcheriminic acid, sordarins, fumonisins, ochratoxin A, and fusaric acid.

With some certain embodiments of aspects of the invention, the secondary metabolite is a modulator of cell surface receptor signaling or a biosynthetic intermediate thereof. The term "cell surface receptor" is as used before. Modulators of cell surface receptor signaling might function by one of several mechanisms including, without limitation, acting as agonists or antagonists, sequestering a molecule that interacts with a receptor such as a ligand, or stabilizing the interaction of a receptor and molecule with which it interacts. Preferred modulators of cell surface signaling include, without limitation, the insulin receptor agonist L-783,281 and the cholecystokinin receptor antagonist asperlicin.

In certain embodiments of aspects of the invention, the secondary metabolite is a plant growth regulator or a biosynthetic intermediate thereof. A "plant growth regulator" is a molecule that controls growth and development of a plant by affecting processes that include, without limitation, division, elongation, and differentiation of cells. Preferred plant growth regulators include, without limitation, cytokinin, auxin, gibberellin, abscisic acid, and ethylene.

In certain embodiments of aspects of the invention, the secondary metabolite is a pigment or a biosynthetic

intermediate thereof. A "pigment" is a substance that imparts a characteristic color. Preferred pigments include, without limitation, melanins and carotenoids.

In certain embodiments of aspects of the invention, the secondary metabolite is an insecticide or a biosynthetic intermediate thereof. An "insecticide" is a molecule that is toxic to insects. Preferred insecticides include, without limitation, nodulisporic acid.

In certain embodiments of aspects of the invention, the secondary metabolite is an anti-neoplastic compound or a biosynthetic intermediate thereof. An "anti-neoplastic" compound is a molecule that prevents or reduces tumor formation. Preferred anti-neoplastic compounds include, without limitation, taxol (paclitaxel) and related taxoids.

The phrase "increased activity" is used herein to refer to a characteristic that results in an augmentation of the inherent negative or positive function of the regulatory protein.

The invention provides variant regulator proteins of secondary metabolite production with increased activity and methods of producing the same. The invention further provides for the identification of specific amino acid residues that are important to the functioning of secondary metabolite regulator proteins. By way of non-limiting example, variant regulator proteins of the secondary metabolite regulator lovE are presented herein.

As known to those skilled in the art, certain substitutions of one amino acid for another may be tolerated at one or more amino acid residues of a wild-type regulator protein absent a change in the structure, activity and/or function of the wild-type protein. Such substitutions are referred to in the art as "conservative" substitutions, and amino acids may be

categorized into groups that identify which amino acids may be substituted for another without altering the structure and/or function of the protein.

As used herein, the term "conservative substitution" refers to the exchange of one amino acid for another in the same conservative substitution grouping in a protein sequence. Conservative amino acid substitutions are known in the art and are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. In a preferred embodiment, conservative substitutions typically include substitutions within the following groups: Group 1: glycine, alanine, and proline; Group 2: valine, isoleucine, leucine, and methionine; Group 3: aspartic acid, glutamic acid, asparagine, glutamine; Group 4: serine, threonine, and cysteine; Group 5: lysine, arginine, and histidine; Group 6: phenylalanine, tyrosine, and tryptophan. Each group provides a listing of amino acids that may be substituted in a protein sequence for any one of the other amino acids in that particular group.

As stated *supra*, there are several criteria used to establish groupings of amino acids for conservative substitution. For example, the importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, *Mol. Biol.* **157:**105-132 (1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. Amino acid hydrophilicity is also used as a criteria for the establishment of conservative amino acid groupings (see, *e.g.*, U.S. Patent No. 4,554,101).

Information relating to the substitution of one amino acid for another is generally known in the art (see, *e.g.*, Introduction to Protein Architecture : The Structural Biology of Proteins, Lesk, A.M., Oxford University Press; ISBN: 0198504748; Introduction to Protein Structure, Branden, C.-I., Tooze, J., Karolinska Institute, Stockholm, Sweden (January 15, 1999); and Protein Structure Prediction: Methods and Protocols (Methods in Molecular Biology), Webster, D.M.(Editor), August 2000, Humana Press, ISBN: 0896036375).

In one embodiment of the first aspect, the invention provides an improved regulator protein comprising an amino acid sequence coding for a variant of the lovE protein having at least one specific mutation that gives rise to greater transcription-activating properties of the regulator protein and/or increased lovastatin synthesis.

By way of non-limiting example, certain amino acid residues and mutations thereof in the lovE regulatory protein of *A. terreus* (SEQ ID NO:91) are identified by the invention described herein. Mutations at residues 31, 41, 52, 73, 101, 111, 133, 141, 153, 281, 367, and 389 of the wild-type lovE protein of *A. terreus* have been identified as being critical for the improvement of *lovE* regulator protein function. Those mutations include: F31L, Q41K, Q41R, T52I, T52N, C73R, P101S, P101Q, V111I, S133L, E141V, E141K, C153Y, C153R, T281A, N367I, N367Y, P389S and P389L. Each mutation, therefore, represents a change of one conservative class of amino acids for another. For example, the mutation F31L represents a change from a Group 6 amino acid residue to a Group 2 amino acid residue at position 31 of the wild-type, lovE regulator protein.

Thus, by way of non-limiting example, regulator proteins of this aspect of the invention include at least

one of the following mutations: (1) a Group 6 amino acid residue mutated to a Group 2 amino acid residue at position 31, for example, the mutation represented by F31L; (2) a Group 3 amino acid residue mutated to a Group 5 amino acid residue at position 41, for example, the mutation represented by Q41K or Q41R; (3) a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 52, for example, the mutation represented by T52I; (4) a Group 4 amino acid residue mutated to a Group 3 amino acid residue at position 52, for example, the mutation represented by T52N; (5) a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 73, for example, the mutation represented by C73R; (6) a Group 1 amino acid residue mutated to a Group 4 amino acid residue at position 101, for example, the mutation represented by P101S; (7) a Group 1 amino acid residue mutated to a Group 3 amino acid residue at position 101, for example, the mutation represented by P101Q; (8) a valine amino acid residue mutated to another Group 2 amino acid residue at position 111, for example, the mutation represented by V111I; (9) a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 133, for example, the mutation represented by S133L; (10) a Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 141, for example, the mutation represented by E141V; (11) a Group 3 amino acid residue mutated to a Group 5 amino acid residue at position 141, for example, the mutation represented by E141K; (12) a Group 4 amino acid residue mutated to Group 6 amino acid residue at position 153, for example, the mutation represented by C153Y; (13) a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 153, for example, the mutation represented by C153R; (14) a Group 4 amino acid residue mutated to a Group 1 amino acid residue at position 281, for example,

the mutation represented by T281A; (15) a Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 367, for example, the mutation represented by N367I; (16) a Group 3 amino acid residue mutated to a Group 6 amino acid residue at position 367, for example, the mutation represented by N367Y; (17) a Group 1 amino acid residue mutated to Group 4 amino acid residue at position 389, for example, the mutation represented by P389S; and/or (18) a Group 1 amino acid residue mutated to a Group 2 amino acid residue at position 389, for example, the mutation represented by P389L.

In other embodiments of the first aspect, the invention provides a variant of the lovE regulator protein with at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen of the above described specific mutations.

In other embodiments of the first aspect, the invention provides an isolated lovE variant regulator protein having the sequence of SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, or SEQ ID NO:65.

In a second aspect, the invention provides a nucleic acid molecule encoding a variant regulator protein of secondary metabolite production of the first aspect of the invention. As used herein, the terms "nucleic acid" or "nucleic acid molecule" refer to a deoxyribonucleotide or ribonucleotide polymer in either single-or double-

stranded form, and unless otherwise limited, would encompass analogs of natural nucleotides that can function in a similar manner as the naturally occurring nucleotide.

In one embodiment of the second aspect, the invention provides a nucleic acid molecule encoding a variant protein of the lovE regulator protein of the first aspect of the invention.

By way of non-limiting example, the invention provides a nucleic acid molecule encoding a lovE variant regulator protein having the sequence of SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, or SEQ ID NO:90.

Poor transformation efficiency and the lack of efficient selection systems frequently precludes the screening of large numbers of variant regulator proteins of secondary metabolites in the organism from which the regulator protein is isolated. For example, there are currently certain technical obstacles to the successful screening of large numbers of variant regulator proteins in the fungus *A. terreus*, an organism that produces the secondary metabolite lovastatin.

The invention described herein takes advantage of the genetically tractable and experimentally amenable organism *Saccharomyces cerevisiae* for screening large numbers of variant regulator proteins of secondary metabolite production. Techniques common to the field of molecular biology are well developed in *S. cerevisiae*, and large numbers of vectors are available to assist the genetic manipulation and cloning of variant regulator proteins involved in secondary metabolite production.

Other genetically tractable organisms could also be used for this purpose.

In a third aspect, the invention provides a method of increasing the activity of a protein that regulates secondary metabolite production comprising: (a) selecting a nucleic acid comprising a polynucleotide encoding a protein regulator of secondary metabolite production; (b) mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; and (c) selecting a variant regulator protein with more activity than the cognate, wild-type protein.

As used herein, "mutating" is used to refer to the deliberate alteration of at least one nucleotide residue of a wild-type, cognate nucleic acid sequence encoding a regulator protein of secondary metabolite production. A deliberate alteration or change in at least one nucleotide residue of a polynucleotide may be accomplished by any method known in the art. The mutation(s) can be made *in vivo* or *in vitro* and can include random, partially random or not random, *i.e.*, directed, mutagenesis techniques.

By way of non-limiting example, *in vivo* mutagenesis can be done by placing this nucleic acid molecule in a cell with a high mutation frequency, i.e. a mutagenic strain. By way of non-limiting example, Muhlrad *et al.* (*Yeast* **8**:79-82 (1992)) have developed a rapid method for localized mutagenesis of yeast genes. As a first step, the region of interest of a gene sequence is first amplified *in vitro* under error-prone polymerase chain reaction (PCR) conditions. Error-prone polymerase chain reaction (PCR) is a method of introducing amino acid changes into proteins. With this technique, mutations are deliberately introduced during the PCR reaction through the use of error-prone DNA polymerases under

specific reaction conditions. With the Muhlrad *et al.* procedure, the PCR product is then co-transformed with a gapped plasmid containing homology to both ends of the PCR product, resulting in *in vivo* recombination to repair the gap with the mutagenized DNA.

There are a variety of commercially available kits that may be used to produce mutant nucleic acid molecules by error-prone PCR (see, e.g., GeneMorph™ PCR Mutagenesis Kit (Stratagene, La Jolla, California); and Diversify™ PCR Random Mutagenesis Kit (BD Biosciences Clontech, Palo Alto, CA). Thus, a plurality of variant, *i.e.*, mutated, regulator proteins of secondary metabolite production may be produced using established mutagenesis techniques.

As used herein, the term "activity" refers to a characteristic of the regulator protein that negatively or positively affects the biological system to bring about a modulation in secondary metabolite production. By way of non-limiting example, the activity is the transcription of downstream genes involved in the biosynthetic pathway of the secondary metabolite of choice. Thus, in the present example, the phrase "more activity" refers to the property of a variant regulator protein to bring about more transcription than that effected by the cognate, wild-type regulator protein.

In certain embodiments of the third aspect, the selected variant regulator protein has more activity in a fungal cell than the cognate, wild-type protein. In certain embodiments of the third aspect, the protein regulator of secondary metabolite production is a transcription factor. In certain embodiments of the fourth aspect, the protein regulator of secondary metabolite production is a transmembrane transporter, a protein that mediates secretion, a kinase, a G-protein, a cell surface receptor, a GTPase activating protein, a

guanine nucleotide exchange factor, a phosphatase, a protease, a phosphodiesterase, a bacterial protein toxin, an importin, an RNA-binding protein, an SCF complex component, an adherin, or a protein encoded within a biosynthetic cluster. . In certain other embodiments of the third aspect, the selected variant regulator protein has more activity in a heterologous cell than the cognate, wild-type protein. In certain embodiments thereof, the heterologous cell is an organism selected from the group consisting of *S. cerevisiae, E. coli, A. nidulans, Candida sp.*, and *N. crassa*. In yet certain other embodiments of the third aspect, the selected variant regulator protein has more activity in a homologous cell than the cognate, wild-type protein. In certain embodiments thereof, the homologous cell is an organism selected from the group consisting of *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp.*, and *Phaffia rhodozyma*.

In certain embodiments of the third aspect, the selected variant regulator protein has more activity in a heterologous cell and a homologous cell than the cognate, wild-type protein. In certain embodiments thereof, the heterologous cell is an organism selected from the group consisting of *S. cerevisiae, E. coli, A. nidulans, Candida sp.*, and *N. crassa* and the homologous cell is an organism selected from the group consisting of *Aspergillus sp., Penicillium sp., Acremonium chrysogenum,*

Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp. and *Phaffia rhodozyma*.

As used herein, the phrase "heterologous cell" refers to a system for gene expression, *i.e.*, an organism for gene expression, that is one other than the organism from which the selected regulator protein of secondary metabolite production has been isolated. Preferred heterologous cells include, but are not limited to, *S. cerevisiae, E. coli, A. nidulans*, and *Candida sp.*,. and *N. crassa*. Particularly preferred are fungal heterologous cells. In an embodiment of the third aspect, the method comprises: (a) selecting a nucleic acid comprising a polynucleotide encoding a protein regulator of secondary metabolite production; (b) mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; and (c) selecting a mutagenized nucleic acid encoding a variant regulator protein with increased activity in a homologous cell than the cognate, wild-type protein.

As used herein, the phrase "homologous cell" refers to a system for gene expression, *i.e.*, an organism for gene expression, that is the organism from which the regulator protein of secondary metabolite production has been isolated. Preferred homologous cells are fungal homologous cells, including, but not limited to, *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp.*,

Tolypocladium sp., *Tricotheicium sp.*, *Fusidium sp.*, *Emericellopsis sp.*, *Cephalosporium sp.*, *Cochliobolus sp.*, *Helminthosporium sp.*, *Agaricus brunescens*, *Ustilago maydis*, *Neurospora sp.*, *Pestalotiopsis sp* and *Phaffia rhodozyma*. (See, Fungal Physiology, Chapter 9 (Secondary(Special) Metabolism), Griffin, D. H., John Wiley & Sons, Inc.; ISBN: 0471166154).

In certain embodiments of the third aspect, the method further comprises selecting a variant regulator protein that also increases production of a secondary metabolite in a cell when compared to the cognate, wild-type protein. In certain embodiments thereof, the cell is a fungal cell. In certain embodiments thereof, the cell is a heterologous cell, preferably selected from the group consisting of *S. cerevisiae*, *E. coli*, *A. nidulans*, *Candida sp.*, and *N. crassa*.

In certain embodiments thereof, the cell is a homologous cell, preferably selected from the group consisting of *Aspergillus sp.*, *Penicillium sp.*, *Acremonium chrysogenum*, *Yarrowia lipolytica*, *Nodulisporium sp.*, *Fusarium sp.*, *Monascus sp.*, *Claviceps sp.*, *Trichoderma sp.*, *Tolypocladium sp.*, *Tricotheicium sp.*, *Fusidium sp.*, *Emericellopsis sp.*, *Cephalosporium sp.*, *Cochliobolus sp.*, *Helminthosporium sp.*, *Agaricus brunescens*, *Ustilago maydis*, *Neurospora sp.*, *Pestalotiopsis sp.*, and *Phaffia rhodozyma*.

Certain embodiments of the aspects of the invention relate to regulator proteins that promote secondary metabolite production by increasing transcription of one or more genes involved with secondary metabolite production. These wild-type sequences may be selected for mutagenesis to create a plurality of variant regulator proteins. The activity of these transcription-

activating variant regulator proteins may be determined by measuring the activity of a reporter gene having the appropriate promoter sequences. These tests are done in a homologous and/or a heterologous cell. Certain embodiments of aspects of the invention are directed to fungal regulator proteins with transcription-activating activity that is tested in fungal heterologous and homologous cells.

Reporter genes are useful for isolating transformants expressing improved variant regulator proteins. The reporter genes may be operably linked to a promoter sequence that is normally regulated by the wild-type regulator protein. Reporter genes include, but are not limited to, genes encoding β-galactosidase (*lacZ*), β-glucoronidase (*GUS*), β-glucosidase, amylase and invertase, amino acid biosynthetic genes, e.g., the yeast *LEU2*, *HIS3*, *LYS2*, *TRP1* genes (or homologous genes from other fungi, such as filamentous fungi, that encode proteins with the similar functional activities), nucleic acid biosynthetic genes, e.g., the yeast *URA3* and *ADE2* genes (or homologous genes from other fungi, such as filamentous fungi, that encode proteins with the similar functional activities), the mammalian chloramphenicol transacetylase (CAT) gene, or any surface antigen gene for which specific antibodies are available. A reporter gene can also be a neomycin phosphotransferase(neo) gene, which encodes neomycin, kanamycin resistance gene and G418 (geneticin) resistance gene. A reporter gene may encode a protein detectable by luminescence or fluorescence, such as green fluorescent protein (GFP). Reporter genes may additionally or alternatively encode any protein that provides a phenotypic marker, for example, a protein that is necessary for cell growth or viability, or a toxic protein that causes cell death.

Alternatively, the reporter gene may encode a protein detectable by a color assay leading to the presence or absence of color.

The choice of reporter gene will depend on the type of cell to be transformed. Preferred reporter genes are those that are operable in fungal cells. It is preferable to have two reporter genes within the cell. One reporter gene, when expressed, provides a growth advantage to transformed cells that are expressing the variant regulator protein. This allows for the isolation of such transformants though selective pressures. The other reporter gene provides a colorimetric marker, such as the *lacZ* gene and its encoded protein, β-galactosidase. Alternatively, the second reporter provides a fluorescent or luminescent marker, such as green fluorescent protein (GFP).

In a fourth aspect, the invention provides a method of increasing production of a secondary metabolite comprising: (a) selecting a nucleic acid comprising a polynucleotide encoding a protein regulator of secondary metabolite production; (b) mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; (c) selecting a variant regulator protein with more activity than the cognate, wild-type protein; and (d) expressing the selected variant regulator protein in a cell, thereby increasing production of the secondary metabolite in the cell.

In certain embodiments of the fourth aspect, the cell is a fungal cell. In certain embodiments of the fourth aspect, the protein regulator of secondary metabolite production is a transcription factor. In certain embodiments of the fourth aspect, the protein regulator of secondary metabolite production is a

transmembrane transporter, a protein that mediates secretion, a kinase, a G-protein, a cell surface receptor, a GTPase activating protein, a guanine nucleotide exchange factor, a phosphatase, a protease, a phosphodiesterase, a bacterial protein toxin, an importin, an RNA-binding protein, an SCF complex component, an adherin, or a protein encoded within a biosynthetic cluster. In certain embodiments of the fourth aspect, the cell is a heterologous cell, preferably selected from the group consisting of *S. cerevisiae, E. coli, A. nidulans, Candida sp.*, and *N. crassa*. In certain other embodiments of the fourth aspect, the cell is a homologous cell, preferably selected from the group consisting of *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp.*, and *Phaffia rhodozyma*.

In certain other embodiments of the fourth aspect, the cell is a heterologous cell and the method further comprises expressing the variant regulator protein in a homologous cell, thereby increasing secondary metabolite production in the homologous cell. In certain embodiments thereof, the heterologous cell is an organism selected from the group consisting of *S. cerevisiae, E. coli, A. nidulans, Candida sp.*, , and *N. crassa* and the homologous cell is an organism selected from the group consisting of *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps*

*sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp.*and *Phaffia rhodozyma.*

In a fifth aspect, the invention provides an isolated variant regulator protein of secondary metabolite production having increased activity compared to a cognate, wild-type protein, made by the process comprising: (a) selecting a nucleic acid comprising a polynucleotide encoding a protein regulator of secondary metabolite production; (b) mutating the nucleic acid to create a plurality of nucleic acid molecules encoding variant regulator proteins of secondary metabolite production; (c) selecting a variant regulator protein with more activity than the cognate, wild-type protein; and (d) recovering the selected variant regulator protein.

In certain embodiments of the fifth aspect, the variant regulator protein selected has more activity in a fungal cell. In certain embodiments of the fifth aspect, the protein regulator of secondary metabolite production is a transcription factor. In certain embodiments of the fifth aspect, the protein regulator of secondary metabolite production is a transmembrane transporter, a protein that mediates secretion, a kinase, a G-protein, a cell surface receptor, a GTPase activating protein, a guanine nucleotide exchange factor, a phosphatase, a protease, a phosphodiesterase, a bacterial protein toxin, an importin, an RNA-binding protein, an SCF complex component, an adherin, or a protein encoded within a biosynthetic cluster. In certain embodiments of the fifth aspect, the variant regulator protein selected has

more activity in a heterologous cell, preferably selected from the group consisting of *S. cerevisiae, E. coli, A. nidulans, Candida sp., Neurospora sp., Pestalotiopsis sp.*, and *N. crassa*. In certain embodiments of the fifth aspect, the variant regulator protein selected has more activity in a homologous cell, preferably selected from the group consisting of *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp.*, and *Phaffia rhodozyma*.

In certain embodiments of the fifth aspect, the variant regulator protein selected has more activity in a homologous cell and a heterologous cell. In embodiments thereof, the heterologous cell is an organism selected from the group consisting of *S. cerevisiae, E. coli, A. nidulans, Candida sp., Neurospora sp., Pestalotiopsis sp.*, and *N. crassa* and the homologous cell is an organism selected from the group consisting of *Aspergillus sp., Penicillium sp., Acremonium chrysogenum, Yarrowia lipolytica, Nodulisporium sp., Fusarium sp., Monascus sp., Claviceps sp., Trichoderma sp., Tolypocladium sp., Tricotheicium sp., Fusidium sp., Emericellopsis sp., Cephalosporium sp., Cochliobolus sp., Helminthosporium sp., Agaricus brunescens, Ustilago maydis, Neurospora sp., Pestalotiopsis sp.*, and *Phaffia rhodozyma*.

In yet another embodiment of the fifth aspect, the variant regulator protein is a variant protein of the lovE protein having at least one of the following mutations: (1) a Group 6 amino acid residue mutated to a

Group 2 amino acid residue at position 31, for example, the mutation represented by F31L;(2) a Group 3 amino acid residue mutated to a Group 5 amino acid residue at position 41, for example, the mutation represented by Q41K or Q41R; (3) a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 52, for example, the mutation represented by T52I; (4) a Group 4 amino acid residue mutated to a Group 3 amino acid residue at position 52, for example, the mutation represented by T52N; (5) a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 73, for example, the mutation represented by C73R; (6) a Group 1 amino acid residue mutated to a Group 4 amino acid residue at position 101, for example, the mutation represented by P101S; (7) a Group 1 amino acid residue mutated to a Group 3 amino acid residue at position 101, for example, the mutation represented by P101Q; (8) a valine amino acid residue mutated to another Group 2 amino acid residue at position 111, for example, the mutation represented by V111I; (9) a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 133, for example, the mutation represented by S133L; (10) a Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 141, for example, the mutation represented by E141V; (11) a Group 3 amino acid residue mutated to a Group 5 amino acid residue at position 141, for example, the mutation represented by E141K; (12) a Group 4 amino acid residue mutated to Group 6 amino acid residue at position 153, for example, the mutation represented by C153Y; (13) a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 153, for example, the mutation represented by C153R; (14) a Group 4 amino acid residue mutated to a Group 1 amino acid residue at position 281, for example, the mutation represented by T281A; (15) a Group 3 amino acid residue

mutated to a Group 2 amino acid residue at position 367, for example, the mutation represented by N367I; (16) a Group 3 amino acid residue mutated to a Group 6 amino acid residue at position 367, for example, the mutation represented by N367Y; (17) a Group 1 amino acid residue mutated to Group 4 amino acid residue at position 389, for example, the mutation represented by P389S; and/or (18) a Group 1 amino acid residue mutated to a Group 2 amino acid residue at position 389, for example, the mutation represented by P389L.

In certain embodiments of this aspect of the invention, the variant protein of the lovE protein sequence has an amino acid sequence of SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, or SEQ ID NO:65.

In another embodiment thereof, the variant protein of the lovE protein is encoded by a nucleic acid molecule having a polynucleotide sequence of SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, or SEQ ID NO:90.

In a sixth aspect, the invention provides a fungus having improved lovastatin production made by the process of transforming a fungal cell with a nucleic acid molecule encoding a variant of the lovE protein of the first aspect of the invention. In an embodiment thereof, the nucleic acid molecule is selected from a nucleic acid molecule of the second aspect of the invention.

In a seventh aspect, the invention provides an improved process for making lovastatin comprising transforming a fungal cell with a nucleic acid molecule encoding a variant of the lovE protein of the first aspect of the invention. In an embodiment thereof, the fungal cell is transformed with a nucleic acid molecule of the second aspect of the invention.

International Patent Application PCT/US99/29583 discloses lovastatin production genes. However, this reference does not provide a mature *lovE* cDNA sequence. The invention herein remedies the shortcoming of this reference by providing a complete cDNA sequence for the *lovE* mRNA.

In an eighth aspect, the invention provides a nucleic acid molecule encoding a lovE protein defined by SEQ ID NO:91. In an embodiment thereof, the invention provides an isolated *lovE* nucleic acid molecule defined by SEQ ID NO:92.

The following examples illustrate the preferred modes of making and practicing the present invention but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results.

EXAMPLES

Example 1: Preparation of Strains and Plasmids

Strain MY2124 was derived from the Sigma 1278b strain background of *S. cerevisiae* and its complete genotype is as follows: *MATα/MATα::LEU2 ura3Δ0 /ura3Δ0 leu2Δ0/leu2Δ0 trp1Δ0::hisG/trp1Δ0::hisG his3Δ0::hisG/his3Δ0::hisG ura3Δ0::lovF-HIS3p-neo/ura3Δ0.* MY2124 can be constructed by mating *S. cerevisiae* strains MY2112 (*MATα ura3Δ0 leu2Δ0 trp1Δ0::hisG his3Δ0::hisG*

ura3Δ0::lovFp-HIS3p-neo) with MY1555 (*matα::LEU2 ura3Δ0 leu2Δ0 trp1Δ0::hisG his3Δ0::hisG*) and isolating zygotes. The *ura3Δ0::lovFp-HIS3p-neo* allele of MY2112 was derived by cotransforming *Sfi*I-linearized plasmid MB2254 with pRS424 (Sikorski and Hieter (1989) *Genetics* 122:19-27) into MY1413 (*MATα leu2Δ0 trp1Δ0::hisG his3Δ0::hisG*). Transformants were selected on SC-Trp media and subsequently screened for 5-fluoro-orotic acid resistance to identify those transformants containing the *ura3Δ0::lovFp-HIS3p-neo* allele. Trp⁻ segregants lacking plasmid pRS424 were isolated by growing the strain under non-selective conditions.

The following oligonucleotides were used in the construction of plasmids.

Table 2: Oligonucleotides Utilized For *LovE* Variant Cloning
MO664 (5'GGCCATGGAGGCCGCTAGCTCGAGTCGACGGCCTAGGTGGCCAGCT3') (SEQ ID NO:1)
MO665 (5'GGCCACCTAGGCCGTCGACTCGAGCTAGCGGCCTCCATGGCCGTAC3') (SEQ ID NO:2)
MO666 (5'GGCGGCCGCTCTAGAACTAGTCTCGAGGGTACC3') (SEQ ID NO:3)
MO667 (5'GGTACCCTCGAGACTAGTTCTAGAGCGGCCGCC3') (SEQ ID NO:4)
MO1794 (5' CACAGCGGCCGCTCAACCTTCCCATTGGGGC3') (SEQ ID NO:5)
MO1793 (5'CACCACTAGTACGCGGGCTGATTCGAC3') (SEQ ID NO:6)
MO1785 (5'CACCACTAGTTATACATTATATAAAGTAATGTG3') (SEQ ID NO:7)
MO1786 (5'CACAGGATCCGTCATCTTTGCCTTCGTTTATC3') (SEQ ID NO:8)
MO195 (5'CGCGGATCCTATTGAACAAGATGGATTGCAC3') (SEQ ID NO:9)
MO196 (5'CCGGAATTCAGAAGAACTCGTCAAGAAG3') (SEQ ID NO:10)
MO841 (5' ACAAAAAAGCAGGCTCCACAATGGCTGCAGATCAAGGTAT3') (SEQ ID NO:11)
MO842 (5' ACAAGAAAGCTGGGTTCATGGAGGAATATTGTTGA3') (SEQ ID NO:12)
MO2278 (5' GGGGATCCAATCGAGGTCCACGACCAGT3') (SEQ ID NO:13)
MO343 (5' GGGGACAAGTTTGTACAAAAAAGCAGGCT3') (SEQ ID NO:14)
MO2273 (5' GGGGATCCGCCAATGGTCCCGTTCAAAC3') (SEQ ID NO:15)
MO2274 (5' ACAAGAAAGCTGGGTTCACAGAATGTTTAGCTCAA3') (SEQ ID NO:16)
MO344 (5' GGGGACCACTTTGTACAAGAAAGCTGGGT3') (SEQ ID NO:17)
MO2624 (5'GCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGG3') (SEQ ID NO:18)
MO2654 (5'CGTCGCGCCATTCGCCATTCAGGCTGCGCAACTGT3') (SEQ ID NO:19)

MO2680	(5'GGACCTTTGCAGCATAAATTACTATACTTCT3') (SEQ ID NO:20)
MO2686	(5'GGCGCGTCCATTCGCCATTCAGGCTGCGCAACTGT3') (SEQ ID NO:21)
MO2681	(5'TAAAACTCTTGTTTTCTTCTTTTCTCTAAAT3') (SEQ ID NO:22)
MO2700	(5'CAGTGAGCGCGCGTAATACGACTCACTATAGGGCGA3') (SEQ ID NO:23)
MO2701	(5' ATACTTCTATAGACACACAAACACAAATACACACAC3') (SEQ ID NO:24)
MO107	(5'CGCGGATCCCGTCGTTTTACAAC3') (SEQ ID NO:25)
MO197	(5'CCCAAGCTTATTATTTTTGACACCAGACCAA3') (SEQ ID NO:26)
MO1293	(5'GGAAGATCTAGCATCGTGGCCAATTTCTTCTAGTTT3') (SEQ ID NO:27)
MO1294	(5'ATAAGAATGCGGCCGCTCAACCTTCCCATTGGGGCGTTTGC3') (SEQ ID NO:28)
MO1787	(5'CACAGGATCCAGCATTATTAATTTAGTGTGTGTATTT3') (SEQ ID NO:29)
MO1788	(5'CACCACTAGTCTCGAGCAGATCCGCCAG3') (SEQ ID NO:30)
MO1793	(5'CACCACTAGTACGCGGGCTGATTCGAC3') (SEQ ID NO:31)
MO1794	(5'CACAGCGGCCGCTCAACCTTCCCATTGGGGC3') (SEQ ID NO:32)
MO511	(5'GGCCATCGATACAAGTTTGTACAAAAAAGCTGAAC3') (SEQ ID NO:33)
MO540	(5'GGCGCCCTATTACACCACTTTGTACAAGAAAGC3') (SEQ ID NO:34)
MO1985	(5'CACACGTCTCCGGCCTCAACCTTCCCATTGGGGCG3') (SEQ ID NO:35)
MO1986	(5'CACACAGATCTCGTGGCCAATTTCTTCTAGTTTGA3') (SEQ ID NO:36)
MO1992	(5'CACACGGATCCACAATGTTACGTCCTGTAGAAACCCC3') (SEQ ID NO:37)
MO1993	(5'CACAGCGGCCGCTTCATTGTTTGCCTCCCTGCTG3') (SEQ ID NO:38)
MO316	(5'GCGGCCGCGGCGCCCGGCCCATGTCAACAAGAAT3') (SEQ ID NO:39)
MO318	(5'CCGCGGCCGAGTGGAGATGTGGAGT3') (SEQ ID NO:40)

Plasmid MB2254 contains the *lovF*p-*HIS3*p-*neo* reporter gene flanked by *URA3* sequence. First primers MO664 (SEQ ID NO:1) and MO665 (SEQ ID NO:2) were annealed and inserted into the *Kpn*I-*Sac*I sites of plasmid pBluescript II KS (Stratagene,). The resulting vector, MB1038, contains a *Sal*I site in the polylinker. Next, the *Spe*I-*Xho*I fragment from pJL164 (Brachmann *et al. Yeast* **14**:115-132 (1998)) containing a deletion of the *URA3* gene with additional flanking sequences was inserted into the *Nhe*I-*Sal*I sites of MB1038 to create MB1053. Primers MO666

(SEQ ID NO:3) and MO667 (SEQ ID NO:4) that contain multiple restriction sites (*Not*I, *Xba*I, *Spe*I, *Xho*I and *Kpn*I) were then annealed together and ligated into the *Sma*I site of MB1053 to create MB1054. Next, the following four fragments were combined in MB1054 to obtain plasmid MB2254. The *lovF* promoter from *A. terreus* genomic DNA was PCR amplified with MO1794 (SEQ ID NO:5) and MO1793 (SEQ ID NO:6) and inserted into MB1054 on a *Not*I-*Spe*I fragment. The *HIS3* basal promoter from pRS403 (Sikorski and Hieter, *Genetics* **122**:19-27 (1989)) was PCR amplified with primers MO1785 (SEQ ID NO:7) and MO1786 (SEQ ID NO:8) and inserted into MB1054 on a *Spe*I-*Bam*HI fragment. Finally, the *neo* gene (PCR amplified with MO195 (*Bam*HI) (SEQ ID NO:) and MO196 (*Eco*RI) (SEQ ID NO:10) from plasmid pYX11 (Xiao and Weaver, *Nucl. Acids Res.* **25**:2985-2991 (1997)) and *CYC1* terminator sequences (*Xho*I-*Kpn*I fragment from pRS426-*GAL*-S (Mumberg, *et al., Nucl. Acids. Res.* **22**:5767-5768 (1994)) were first combined in pRS416 (Sikorski and Hieter, *Genetics* **122**:19-27 (1989)) and then cut out with *Bam*HI-*Kpn*I and inserted into MB1054 to create MB2254.

The *lovF*p-*HIS3*p-*neo* reporter in MY2124 can confer resistance to the drug geneticin (G418). It was empirically determined that MY2124 (untransformed or transformed with parental plasmids MB2478 (*CYC1-lovE/CEN*) or MB2848 (*CYC1-lovE/At274/CEN*) was unable to grow on YPD media supplemented with 100 µg /ml G418. Plasmid MB2478 contains the *CYC1* promoter operationally linked to the entire *A. terreus lovE* open reading frame. The *CYC1* promoter is a relatively weak promoter and thus the *lovE* ORF in MB2478 was expressed at low levels. MB2478 was the parental vector plasmid for creating full length *lovE* variants. Plasmid MB2848 contains the *CYC1* promoter operationally linked to a chimeric open reading frame

consisting of the *A. terreus lovE* DNA binding domain fused to the carboxy-terminal portion of the *At274* gene (U.S. Serial No. 60/257,431, filed December 22, 2000).

MB2848 was used to create *lovE* variants in which the DNA binding domain was not mutated. Both MB2478 and MB2848 contain yeast CEN and autonomously replicating sequences and both are maintained at 1-2 copies per cell. In contrast to strains transformed with MB2478 or MB2848, strains transformed with plasmid MB1644 (*TEF1-lovE*/2 micron) were able to grow on G418-supplemented YPD media. The *lovE* gene of MB1644 is under control of the constitutively strong *S. cerevisiae TEF1* promoter. MB1644 contains a 2-micron origin for high-copy replication in yeast. An objective of these studies was to identify *lovE* variants which when expressed at low levels could confer G418 resistance similar to the highly expressed wild-type *lovE* molecule of MB1644. *S. cerevisiae* expression vectors used in these studies were constructed as follows.

MB968 is a low copy *S. cerevisiae URA3* based expression vector. MB968 was created by inserting the *Eco*RV fragment (containing the destination cassette) from gateway pEZC7201 (Invitrogen™, Carlsbad, CA) into *Xho*I/*Sal*I (filled in with Klenow) linearized pRS416 CYC1 (Mumberg, *et al., Gene* **156**:119-122 (1995)).

MB1644 and MB2478 are *URA3*-based *S. cerevisiae* expression plasmids that contain the wild-type *lovE* gene. They are both derivatives of MB1199. MB1199 was created by using primers MO841 (SEQ ID NO:11) and MO842 (SEQ ID NO:12) to amplify the *lovE* ORF from *A. terreus* cDNA. Gateway (Invitrogen™, Carlsbad, CA) Cloning Technology (US Patent 5,888,732) was used to clone the *lovE* PCR fragment into the gateway entry vector pDONR206 (Invitrogen™, Carlsbad, CA) to create MB1199. Similarly, Gateway Cloning Technology was used to transfer the *lovE*

ORF from MB1199 into MB968 to create MB2478 and into MB969 (U.S. Serial No. 60/198,335, filed April 18, 2000) to create MB1644.

MB2848 is a derivative of MB968 that contains a *lovE-AT274* chimera. The *lovE* portion of MB2848 was derived by using oligos MO841 (SEQ ID NO:11) and MO2278 (SEQ ID NO:13) to PCR amplify the *lovE* DNA binding domain from *A. terreus* cDNA. A second round of PCR was performed with primers MO343 (SEQ ID NO:14) and MO2278 to add appropriate Gateway Cloning Technology compatible sequences. The *At274* portion of MB2848 can be derived by using primers MO2273 (SEQ ID NO:15) and MO2274 (SEQ ID NO:16) to PCR amplify the carboxy-terminal domain of *At274* from *A. terreus* cDNA. A second round of PCR was performed with primers MO344 (SEQ ID NO:17) and MO2273 to add appropriate Gateway Cloning Technology compatible sequences. The *lovE* and *At274* PCR products were cut with *Bam*HI and purified over a QIAquick PCR purification kit (Qiagen, Valencia, CA) according to manufacturer's instructions. Finally, the products were mixed 3-4 hours in a standard ligation reaction and used in Gateway entry and destination reactions to create MB2848.

Gateway cloning technology was used to clone the lovE variants of interest into plasmid MB1419 which is a filamentous fungal expression vector. The MB1419 fungal selection marker is the *A. nidulans GPD* promoter controlling the *ble* gene from *S. hindustanus*. The transgene is controlled by the *A. nidulans PGK* promoter. *A. terreus* strain MF117 is a derivative of *A. terreus strain* ATCC 20542.

Example 2: PCR Mutagenesis of the *lovE* DNA Binding Domain

The zinc finger DNA binding domain of *lovE* is encoded by nucleotides 100-201 (SEQ ID NO:92). Oligos MO2624

(SEQ ID NO:18) and MO2654 (SEQ ID NO:19) were used to PCR amplify a *lovE* containing fragment from plasmid MB2478. The 1.7 kb product contains nucleotides 212-1410 of *lovE* and ~500 bp of flanking vector sequence. Two rounds of standard PCR (1.5 mM $MgCl_2$) were performed with Amplitaq DNA polymerase (Applied Biosystems, Foster City, Ca) according to the manufacturer's instructions.

Plasmid MB2848 was cut with *Kpn*I-*Bam*HI to release a 1.1 kb fragment containing the *At274* portion of the *lovE-At274* chimeric open reading frame. The remaining 5.5 kb vector sequence retains the *lovE* DNA binding domain.

Example 3: PCR Mutagenesis of the *lovE* Open Reading Frame

lovE open reading frame insert was prepared according to the following procedure. Oligo pairs MO2680 (SEQ ID NO:20) /MO2686 (SEQ ID NO:21), MO2681 (SEQ ID NO:22) /MO2686, and MO2700 (SEQ ID NO:23) /MO2701 (SEQ ID NO:24) were used to PCR amplify the entire *lovE* open reading frame from plasmid MB2478. The PCR products differ in the amount of 5' and 3' vector sequence flanking the *lovE* open reading frame.

PCR was performed using a GeneMorph PCR mutagenesis kit (Stratagene, La Jolla, Ca) according to manufacturer's instructions to achieve medium and high range mutation frequencies.

Plasmid MB2478 was cut with *Asp*718/*Xba*I to release a 1.7 kb fragment. The remaining 5.0 kb vector sequence completely lacks *lovE* ORF sequence.

Example 4: Transformation and Selection for G418R Isolates

All PCR products were purified using a QIAquick PCR purification kit (Qiagen) according to manufacturer's instructions. All vectors were gel purified using a

QIAquick gel extraction kit (Qiagen) according to manufacturer's instructions.

The mutagenesis strategy of Muhlrad *et al.* (*Yeast* **8**:79-82 (1992))was used which involves cotransforming a mutated PCR product and gapped plasmids into *S. cerevisiae*, and then screening for *in vivo* recombinants having the desired phenotype).

Transformation of *Saccharomyces cerevisiae* was accomplished by the lithium acetate/single-stranded carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) protocol (Woods R.A. and Gietz R.D. *Methods Mol. Biol.* **177**:85-97 (2001)) with a 1:5 molar ratio of vector:insert DNA to generate >55,000 *in vivo* recombinant transformants on SC-Ura plates. Transformants were transferred by replica printing to YPD plates containing 100 µg/ml G418 and allowed to grow for 2-4 days at 30°C (Figure 1).

Drug resistant clones were confirmed in secondary assays including growth on G418 concentrations up to 2000 µg/ml. The plasmid-dependence of the phenotype was determined by observing the re-appearance of drug sensitivity correlating with loss of the library plasmid. *lovE* variant plasmids were recovered from promising candidates (Hoffman and Winston (1986) *Gene* 57:267). More than 70 *lovE* variants were identified and definitively characterized by DNA sequence and/or restriction digestion analysis.

Table 3 summarizes the G418 resistance phenotype and sequence analysis of 26 of these variants.

Table 3: Variant lovE Mutations

lovE allele	*lovFp-neo Mediated G418R*	MO oligos used for random PCR mutagenesis	Amino Acid Change 1	Amino Acid Change 2	Amino Acid Change 3	Amino Acid Change 4	Amino Acid Change 5	Amino Acid Change 6	Amino Acid Change 7	Amino Acid Change 8	Amino Acid Change 9	Amino Acid Change 10	Amino Acid Change 11
1	-/+	2624/2654	H253R	S341P									
2	+/-	2624/2654	R121W	S133L	S322G								
3	+++	2624/2654	C73R	A83V	T135I								
4	++	2624/2654	C73R	E177G									
5	++	2624/2654	C73R										
6	+/-	2624/2654	C153Y	E197K	T281A								
7	+	2624/2654	C73R	T256A	N466S								
8	+++	2624/2654	C73R	E141V									
9	++	2624/2654	C73R	E303K									
10	+++	2624/2654	Q41K										
16	+++	2680/2686	Q41K	P16A	G23S	T9M	Q362E						
19	+/-	2700/2701	R21H	S34A	Q80H	A84S	E303D	H374D	A440T	A441V	C445S	P469S	
20	+	2700/2701	F31L	T409I									
21	+++	2700/2701	F31L	M97I	E113D	D146N	P163S	N367I	H458Y				
30	+/-	2681/2686	I43V	Q295L									
31	++	2680/2686	F31L	P101S	C153R	C159S	E162K	R293L	S311N				
32	++	2680/2686	L14I	E18V	G138C	E338G	V361L	P389S	N400S				
33	++	2680/2686	Q41R	S174Y	A402T								
34	++	2680/2686	F31L	T52I	P101Q	P108S	V111I						
36	+/-	2700/2701	D85N	I143F	M232I	T315I	S382Y	M385K					
37	++	2700/2701	T46I	Q62R	K77R	S323C	N367Y	V373I					
38	-/+	2700/2701	Q41R	T294I	P310L	G337D	P389L	A394V	G436S				
39	+	2680/2686	T52N	V111I	T139	V184I	T281A						
40	+++	2680/2686	Q41R	D4E	V87I	D110E	E141K	A189T	N276D	T347R	N367I	Q377R	A425T
41	-/+	2680/2686	D131N	S133L	R312G	A429G							
wild-type	-	N/A	N/A										

Table 4 summarizes amino acid substitutions that were isolated multiple times, suggesting that they are particularly important for improving *lovE* variant activity on *lovF*p-*HIS3*p-*neo* expression.

Table 4: *lovE* Mutations Isolated Multiple Times

Amino Acid Change	Number of Times Isolated in *lovE* 1-41	*lovE variant*
F31L	4	20, 21, 31, 34
Q41K	2*	10, 16
Q41R	3*	33, 38, 40
T52I/T52N	1 each	34, 39
C73R	6*	3, 4, 5, 7, 8, 9
P101S/P101Q	1 each	31, 34
V111I	2	34, 39
S133L	2	2, 41
E141V, E141K	1 each	8, 40
C153Y/C153R	1 each	6, 31
T281A	2	6, 39
N367I/N367Y	2/1	21, 40, 37
P389S/P389L	1 each	32, 38

* allele was isolated in additional *lovE* variants that were not fully sequenced

Example 5: Increased *lovF-lacZ* Expression in *S. cerevisiae*

In order to quantify the increase in *lovF* expression, β-galactosidase activity was measured in *lovE* variant transformed *S. cerevisiae* strains that also harbored *lovF*p-lacZ reporter derivative plasmids. *lovF-lacZ* reporter derivative plasmids were constructed as follows.

Plasmid MB1918 contains the *lovF*p-*lacZ* reporter gene. It can be derived from pRS424 (Sikorski and Hieter (1989) *Genetics* 122:19-27). First, primers MO107 (SEQ ID NO:25) and MO197 (SEQ ID NO:26) are used to PCR amplify the lacZ gene from Yep355 (Myers, *et al., Gene*

45:299-310 (1986)). This lacZ-containing fragment was inserted into the *Bam*HI-*Hind*III sites of pRS416 (Sikorski and Hieter, *Genetics* **122**:19-27 (1989)). This same *lacZ* fragment can be cut out of the resulting vector with *Kpn*I-*Not*I and inserted into the same sites of pRS424 to create pRS424-lacZ. Primers MO1293 (SEQ ID NO:27) and MO1294 (SEQ ID NO:28) are used to PCR amplify a 2.09 kb fragment of the *lovF* promoter from *A. terreus* genomic DNA. The *lovF* promoter fragment was then cut with *Not*I-*Bgl*II and inserted into *Not*I-*BamH*I linearized pRS424-*lacZ*.

Plasmid MB2114 contains the *lovF*p-*CYC1*p-lacZ reporter gene. It can be derived from pRS424-lacZ (see MB1918 plasmid construction). Primers MO1787 (SEQ ID NO:29) and MO1788 (SEQ ID NO:30) are used to amplify the 264 bp basal *CYC1* element from pRS415 CYC1 (Mumberg, *et al., Gene* **156**:119-122 (1995)). This 264 bp fragment was inserted upstream of the pRS424-lacZ derivative which has been digested with *Spe*I-*Bam*HI. Finally, the *lovF* promoter from MB1918 was PCR amplified with MO1793 (SEQ ID NO:31) and MO1794 (SEQ ID NO:32) and inserted into the *Not*I-*Spe*I sites to create MB2114.

Yeast strains utilized in this study include strains MY2145 and MY2159, which are both derived from the *S. cerevisiae* sigma 1278b strain background; the genotypes are both strains are as follows: *MAT***a** *ura3Δ0 leu2Δ0 his3Δ::hisG trp1Δ0::hisG*. MY2145 and MY2159 contain the *lovF*p-lacZ reporter plasmids MB2114 and MB1918, respectively.

MY2124 transformed with individual *lovE* variant plasmids was mated to *S. cerevisiae* strains MY2154 and MY2159. Diploids were selected on SC-UraTrp media. Multiple diploids from each individual mating were assayed for *lovF*p-*lacZ* expression using 96 well format β-

galactosidase assays. For β-galactosidase assays, cells were transferred from transformation plates to 96-well microtiter plates containing 200 µl Z buffer. 12 strains were transferred simultaneously using a 12-channel multi-pipettor to scoop cells from transformation plates. Duplicate samples were prepared for all assays. OD_{600} readings were taken on samples in Z buffer. These values were used to normalize for equal cell number in all assays. After determining OD_{600}, 150 µl of each sample in Z buffer was transferred onto a Millipore Multiscreen Assay System (Nitrocellulose Immobilon NC), filtered, and then washed by filtering 200 µl Z buffer. 100 µl Z buffer with βME and detergents was then added to each well, as was 20 µl 4 mg/ml ONPG. Reactions were incubated at 30°C, stopped with 50µl 1 M Na_2CO_3, filtered into a polystyrene 96-well assay plate, and OD_{420} was determined for each assay well. β-galactosidase units were determined using the Miller formula (O.D. 420 X 1000)/ (OD600*minutes*volume in mL). Z buffer is made by dissolving the following in 1 L of water (16.1 g Na_2HPO_4-$7H_2O$, 5.5g NaH_2PO_4-H_2O, 0.75 g KCl and 0.246 g $MgSO_4$-$7H_20$). Z buffer with detergents and βME is made as follows: 9.8 ml Z buffer, 100 µl 20 mg/ml CTAB, 100 µl 10 mg/ml sodium deoxycholate, and 69 µl βME Control plasmids utilized in these studies included MB968, MB2478 and MB1644.

Results of these studies are presented in Figures 2-5, demonstrating increased transcription-activating properties of the *lovE* variants disclosed herein.

Example 6: Secondary Metabolite Production

Transformation of filamentous fungi was performed according to the following procedure. Protoplasts were generated by inoculating rich media with spores. Spores were allowed to germinate for about 20 hrs or until germ tubes were between 5 and 10 spore lengths. The germlings were centrifuged and washed twice with sterile distilled water and once with 1 M magnesium sulfate. Germlings were then resuspended in 1M magnesium sulfate containing approximately 2 mg/ml of Novozyme. Tubes were then incubated at 30°C shaking at 80 RPM for about 2 hrs or until most of the hyphae were digested and protoplasts were abundant. Protoplasts were filtered through one layer of Miracloth. At least one volume of STC was added and protoplasts were centrifuged. Protoplasts were washed twice with STC. Protoplasts then were resuspended in 1ml STC and counted in a hemacytometer. A final concentration of approximately 5 x 10^7 protoplasts/ml were frozen in a 9:1:0.1 solution of STC, SPTC and DMSO in a Nalgene Cryo cooler at -80°C (cools -1°C/min).

Solutions for transformation were as follows: STC (0.8 M Sorbitol, 25 mM Tris-HCl pH 7.5, 25 mM $CaCl_2$) and SPTC (0.8 M Sorbitol, 40% PEG 4000, 25 mM Tris-HCl pH 8, 50 mM $CaCl_2$). Transformation was accomplished according to the following protocol. 1-5 µg of DNA comprising a *lovE* variant according to the invention in a fungal expression vector was placed in a 50 ml Falcon tube. 100 µl of previously frozen protoplasts were added to the DNA, gently mixed, and then incubated on ice for 30 min. 15 µl of SPTC was added, followed by mixing by tapping and incubation at RT for 15 min. 500 µl SPTC was added and mixed well by tapping and rolling, then incubated at RT for 15 min. 25 mls of regeneration minimal medium was added, mixed well and poured on plates containing 25 mls

of regeneration minimal medium with 2X the concentration of selection drug.

Transformation plates were incubated at 26°C for 5-6 days or until colonies started to appear. Regeneration minimal medium contains trace elements, salts, 25 mM sodium nitrate, 0.8 M Sucrose, and 1% agarose at pH 6.5. The selection drug that was used successfully with *A. terreus* is phleomycin, a broad-spectrum glycopeptide antibiotic. Transformants were picked onto new plates with a toothpick (if the fungus was sporulating) or with sterile forceps (if the fungus did not sporulate). Purification plates contained minimal medium (same as regeneration minimal medium but containing 2 % instead of 0.8 M sucrose) and 1X drug concentration. Picked transformants were incubated at 26°C for 5-6 days.

Transformants were grown in production media for secondary metabolite production. Briefly, for *A. terreus* and lovastatin production, spores were used as the inoculum. Spores were obtained from the purification plate by using a wooden inoculation stick. The medium was RPM containing corn steep liquor, sodium nitrate, potassium phosphate, magnesium sulfate, sodium chloride, P2000 (Dow chemical), trace elements and lactose or glucose as carbon source. The medium was pH 6.5. Flasks were incubated at 26°C with shaking at 225 RPM. For static 96-well cultures, the same medium was used and the spores were obtained from the purification plate with a wooden toothpick. 96-well plates were incubated, without shaking at 26°C.

Sampling was done after after 5 days for lovastatin.For shake flask experiments 1-1.5 mls of supernatant was placed into 96-well plates, which were centrifuged and supernatants transferred to new 96-well plates. Samples were frozen at -80°C for storage or for later assays.

Cultures that were grown standing in a 96-well plate were centrifuged and the supernatant was transferred to a new 96 well plate. Samples were frozen at -80°C.

Example 7: Measurement of Secondary Metabolite Production

The concentration of the secondary metabolite lovastatin was determined by enzyme inhibition assay (Figure 6). Briefly, 10 µL of sample was removed and diluted 1:100 in H_2O. 10 µl of this diluted broth was assayed in a reaction (200 µL total) containing 1 mM HMGCoA, 1 mM NADPH, 0.005 mM DTT and 5 µl $(His)_6$HMGR. The disappearance of absorbance at 340 nm was observed over time. This represents the disappearance of NADPH, and lovastatin inhibits this reaction.

The initial velocities were calculated for the reactions containing samples, adjusted for dilution, and compared to reactions containing lovastatin standards to determine levels of metabolite produced. $(His)_6$HMGR was expressed in *Saccharomyces cerevisiae* and purified with a nickel column.

The results from ten individual transformants for each allele are shown in standard box plot format in Figure 6. Lovastatin concentration from the corresponding wild-type *lovE* control is shown in matching fill pattern. For example, *lovE* alleles 2, 7, 8 and 9 were all transformed and assayed at the same time as the non-hatched wild-type control. The horizontal line in each individual box represents the median.

Lovastatin concentration was also determined by high pressure liquid chromatography (HPLC). Briefly, 100 µL of broth sample was removed and diluted 1:10 into 70% H_2O-30% acetonitrile (900 µl). This mixture was spun down to pellet debris at 13000 RPM for 5 minutes. 900 µl of this

diluted broth was transferred to a vial and the sample was analyzed by HPLC. 10 µl were injected into a Waters HPLC system (996 photo-diode array detector, 600 E pump controller and 717 autosampler) equipped with a YMC-Pack ODS column (Aq-302-3, 150 x 4.6 mm ID, S-3 µM pore size) and eluted with isocratic 40% aqueous acetic acid (0.7%)-60% acetonitrile for 8 minutes. Lovastatin was detected at 238 nm to have a retention time of 6.5 minutes and was quantified using a calibration curve created from pure lovastatin samples.

The results from ten individual transformants for each *lovE* variant are shown in standard box plot format in Figure 7A and 7B. Thirty individual wild-type *lovE* transformants and ten individual MB2143 negative control transformants were tested. Identical controls are plotted in Figures 7A and 7B.

PCR analysis of *A. terreus* transformants demonstrates that greater than fifty percent of the transformants contain the transgene. Variability in levels of transgene expression can presumably be influenced by integration site and copy number. *lovE* variants containing identical amino acid substitutions are labeled.

The amino acid and nucleic acid sequences of *lovE* variant sequences are presented in Table 5 and Table 6, respectively.

Table 5: Amino Acid Sequences of Variants of the *lovE* Gene

***lovE*-1**
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadcrqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtssssghssvd
tipffsenlpigelfpyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:41)

lovE-2
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntswqfldppdsy
dwlwtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghgsvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:42)

lovE-3
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsrvadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswisigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:43)

lovE-4
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvgkaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:44)

lovE-5
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:45)

lovE-6
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqydggfscqleptlpdlpspfestvekaplppvssdiaraasaq
rklfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvrilaaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:46)

lovE-7
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgaldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnsipp (SEQ ID NO:47)

lovE-8
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgaldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnsipp (SEQ ID NO:48)

lovE-9
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgaldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnsipp (SEQ ID NO:49)

lovE-10
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvyserrpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgaldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnsipp (SEQ ID NO:50)

lovE-16
maadqgifmnsvtlsavegsrtsgtlprrafrrscdrchakkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvellreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:51)

lovE-19
maadqgiftnsvtlspvegshtggtlprrafrracdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrhsrasdlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmspldgsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvdsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtitvlrrsyedifslark
hkhgmlrdlnnips (SEQ ID NO:52)

lovE-20
maadqgiftnsvtlspvegsrtggtlprralrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpitpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:53)

lovE-21 maadqgiftnsvtlspvegsrtggtlprralrrscdrchaqkikctgnkevtgrapcqrcqqagl rcvysercpkrklrqsraadlvsadpdpclhissppvpsqslpldvsdshssntsrqfldppdsy dwswtsigtdeaidtncwglsqcdggfscqlestlpdlpspfestvekaplppvssdiaraasaq relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd tipffsenlpigelfsyvdplthalfsacttlhvgvqllreieitlgvhsaqgiaasismsgepg ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark hkygmlrdlnnipp (SEQ ID NO:54)
lovE-30 maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkvkctgnkevtgrapcqrcqqagl rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec lrtknlftavhcyilnvriltaiselllsqirrtlnshmsplegsrsqspsrddtsssghssvd tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark hkhgmlrdlnnippc (SEQ ID NO:55)
lovE-31 maadqgiftnsvtlspvegsrtggtlprralrrscdrchaqkikctgnkevtgrapcqrcqqagl rcvysercpkrklrqsraadlvsadpdpclhmsspsvpsqslpldvseshssntsrqfldppdsy dwswtsigtdeaidtdcwglsqrdggfssqlkptlpdlpspfestvekaplppvssdiaraasaq relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec lrtknlftavhcyilnvriltaiselllsqirltqnshmsplegsrsqspnrddtsssghssvd tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark hkhgmlrdlnnipp (SEQ ID NO:56)
lovE-32 maadqgiftnsvtispvvgsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy dwswtsictdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd tipffsenlpigglfsyvdplthalfsacttlhvglqllreneitlgvhsaqgiaasismsgesg ediartgatssarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark hkhgmlrdlnnipp (SEQ ID NO:57)
lovE-33 maadqgiftnsvtlspvegsrtggtlprrafrrscdrcharkikctgnkevtgrapcqrcqqagl rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfeytvekaplppvssdiaraasaq relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg ediartgatnstrceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark hkhgmlrdlnnipp (SEQ ID NO:58)
lovE-34 maadqgiftnsvtlspvegsrtggtlprralrrscdrchaqkikctgnkevigrapcqrcqqagl rcvysercpkrklrqsraadlvsadpdpclhmsspqvpsqslsldiseshssntsrqfldppdsy dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtsssghssvd tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark hkhgmlrdlnnipp (SEQ ID NO:59)

lovE-36
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraanlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeafdtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigiffnasrrllvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddissssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaayisksgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:60)

lovE-37
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikcignkevtgrapcqrcqragl
rcvysercpkrrlrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsrddtssssghscvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreyeitlgihsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:61)

lovE-38
maadqgiftnsvtlspvegsrtggtlprrafrrscdrcharkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
dwswtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirriqnshmsplegsrsqslsrddtssssghssvd
tipffsenlpidelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgelg
edivrtgatnsarceeqpttpaarvlfmflsdegafqeaksagsrsrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:62)

lovE-39
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevngrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldiseshssntsrqfldppdsy
dwswtsigideaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppissdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvrilaaiselllsqirrtqnshmsplegsrsqspsrddtssssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:63)

lovE-40
maaeqgiftnsvtlspvegsrtggtlprrafrrscdrcharkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlisadpdpclhmssppvpsqslplevseshssntsrqfldppdsy
dwswtsigtdkaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssditraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyildvriltaiselllsqirrtqnshmsplegsrsqspsrddtssssghssvd
tipffsenlpigelfsyvdplrhalfsacttlhvgvqllreieitlgvhsargiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegtfqeaksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:64)

lovE-41
maadqgiftnsvtlspvegsrtggtlprrafrrscdrchaqkikctgnkevtgrapcqrcqqagl
rcvysercpkrklrqsraadlvsadpdpclhmssppvpsqslpldvseshssntsrqfldppdsy
nwlwtsigtdeaidtdcwglsqcdggfscqleptlpdlpspfestvekaplppvssdiaraasaq
relfddlsavsqeleeillavtvewpkqeiwthpigmffnasrrlltvlrqqaqadchqgtldec
lrtknlftavhcyilnvriltaiselllsqirrtqnshmsplegsrsqspsgddtssssghssvd
tipffsenlpigelfsyvdplthalfsacttlhvgvqllreneitlgvhsaqgiaasismsgepg
ediartgatnsarceeqpttpaarvlfmflsdegafqegksagsrgrtiaalrrcyedifslark
hkhgmlrdlnnipp (SEQ ID NO:65)

5

Table 6: DNA Sequences of Variants of the *lovE* Gene

***lovE*-1**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAGTTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCGTCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCCCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:66)

***lovE*-2**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCTGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTTGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAGTGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACGGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:67)

***lovE*-3**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGACGCCCCAAGCGCAAGCTACGCCAATCCAGGGTAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGATCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:68)

***lovE*-4**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGACGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGGAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:69)

***lovE*-5**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGACGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACTACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:70)

***lovE*-6**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATATGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAAAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGGCCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:71)

***lovE*-7**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGACGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCGCACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAGTATTCCTCCATGA (SEQ ID NO:72)

***lovE*-8**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGACGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGTGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:73)

***lovE*-9**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGACGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
TTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCAC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAACGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGAAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:74)

***lovE*-10**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCAAAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGCTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:75)

***lovE*-16**

ATGGCTGCAGATCAAGGTATATTCATGAACTCGGTCACTCTCTCTGCAGTGGAGGGTTCACGCAC
CAGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCAAAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACAGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTATCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACTAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTAGAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:76)

***lovE*-19**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACACAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCGCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCATTCCAGGGCATCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGACG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTATTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTAGACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCACAGTACTGCGACGAAGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTTCATGA (SEQ ID NO:77)

***lovE*-20**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCACTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGATCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:78)

***lovE*-21**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCACTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATATCCTCGCCTCCAGTGCCCTCACAGAGCTTACCGC
TAGACGTATCCGATTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTAACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGTCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCTAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGATTGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCAACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAATATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:79)

***lovE*-30**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGGTCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCTGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:80)

***lovE*-31**

ATGGCTGCAGATCAAGGTATATTCACGAACTCCGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTACGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGTTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTTCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ACGTGATGGAGGCTTCAGCTCTCAGTTAAAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTACTGTCGCAAATTAGGCTGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAACAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:81)

***lovE*-32**

ATGGCTGCAGATCAAGGTATATTCACTAACTCGGTCACTATCTCGCCAGTGGTGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGTTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTTGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGGGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGCTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAATCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAGTTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:82)

5

***lovE*-33**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACGAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
ATACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCACAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:83)

lovE-34

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTGCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTATTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTATACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCAAGTGCCCTCACAGAGCTTGTCGC
TAGACATATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCATTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:84)

lovE-36

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCACCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGAATCTCGT
CTCTGCTGACCCAGATCCCTGCTTACACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTTTTGACACTGACTGCTGGGGGCTATCCCA
ATGTGATGGAGGCTTCAGCTGTCAGCTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATCTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAGCAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACATCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTACATCAGCAAGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTGTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:85)

***lovE*-37**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTATTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAACGGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAGGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCTTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCTCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCTGTGTCGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGTATGAGA
TTACTCTGGGAATACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGATCTCAACAATATTCCTCCATGA (SEQ ID NO:86)

***lovE*-38**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACGAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAAGCTGGACTT
CGATGCGTCTATAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGCTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGATCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCTGAGCAGAGACGACACCAGCAGCAGTAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGATGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACTAGGC
GAGGATATAGTCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAAGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:87)

***lovE*-39**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCACCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTAATGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCCCAGAGCTTGCCGC
TAGACATATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCATTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGATATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGGCCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:88)

***lovE*-40**

ATGGCTGCAGAACAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACGAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGTGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCAT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCGCCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGAAGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
GACTGGTCGTGGACCTCGATTGGCACTGACAAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTTGAGT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTACTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGGATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCAGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAG
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGATTGAGA
TTACTCTGGGAGTACACTCCGCCCGGGGCATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGACTTTCCAGGAGGCAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:89)

***lovE*-41**

ATGGCTGCAGATCAAGGTATATTCACGAACTCGGTCACTCTCTCGCCAGTGGAGGGTTCACGCAC
CGGTGGAACATTACCCCGCCGTGCATTCCGACGCTCTTGTGATCGGTGTCATGCACAAAAGATCA
AATGTACTGGAAATAAGGAGGTTACTGGCCGTGCTCCCTGTCAGCGTTGCCAGCAGGCTGGACTT
CGATGCGTCTACAGTGAGCGATGCCCCAAGCGCAAGCTACGCCAATCCAGGGCAGCGGATCTCGT
CTCTGCTGACCCAGATCCCTGCTTGCACATGTCCTCACCTCCAGTGCCCTCACAGAGCTTGCCGC
TAGACGTATCCGAGTCGCATTCCTCAAATACCTCCCGGCAATTTCTTGATCCACCGGACAGCTAC
AACTGGTTGTGGACCTCGATTGGCACTGACGAGGCTATTGACACTGACTGCTGGGGGCTGTCCCA
ATGTGATGGAGGCTTCAGCTGTCAGTTAGAGCCAACGCTGCCGGATCTACCTTCGCCCTTCGAAT
CTACGGTTGAAAAAGCTCCGTTGCCACCGGTATCGAGCGACATTGCTCGTGCGGCCAGTGCGCAA
CGAGAGCTTTTCGATGACCTGTCGGCGGTGTCGCAGGAACTGGAAGAGATCCTTCTGGCCGTGAC
GGTAGAATGGCCGAAGCAGGAAATCTGGACCCATCCCATCGGAATGTTTTTCAATGCGTCACGAC
GGCTTCTTACTGTCCTGCGCCAACAAGCGCAGGCCGACTGCCATCAAGGCACACTAGACGAATGT
TTACGGACCAAGAACCTCTTTACGGCAGTACACTGTTACATATTGAATGTGCGGATTTTGACCGC
CATATCGGAGTTGCTCCTGTCGCAAATTAGGCGGACCCAGAACAGCCATATGAGCCCACTGGAAG
GGAGTCGATCCCAGTCGCCGAGCGGAGACGACACCAGCAGCAGCAGCGGCCACAGCAGTGTTGAC
ACCATACCCTTCTTTAGCGAGAACCTCCCTATTGGTGAGCTGTTCTCCTATGTTGACCCCCTGAC
ACACGCCCTATTCTCGGCTTGCACTACGTTACATGTTGGGGTACAATTGCTGCGTGAGAATGAGA
TTACTCTGGGAGTACACTCCGCCCAGGGTATTGCAGCTTCCATCAGCATGAGCGGGGAACCAGGC
GAGGATATAGCCAGGACAGGGGCGACCAATTCCGCAAGATGCGAGGAGCAGCCGACCACTCCAGC
GGCTCGGGTTTTGTTCATGTTCTTGAGTGATGAAGGGGCTTTCCAGGAGGGAAAGTCTGCTGGTT
CCCGAGGTCGAACCATCGCAGCACTGCGACGATGCTATGAGGATATCTTTTCCCTCGCCCGCAAA
CACAAACATGGCATGCTCAGAGACCTCAACAATATTCCTCCATGA (SEQ ID NO:90)

Equivalents

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompasssed by the following claims.